| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 5/G
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | Ruxolitinib |
| CAS No. | 941678-49-5 |
| Molecular formula | C17H18N6 |
| Molecular weight | 306.37 |
| Purity | 99% |
What is Ruxolitinib
Ruxolitinib is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea.
Ruxolitinib competes with ATP for binding to the catalytic site in the kinase domain and thus inhibits not only the mutated JAK2 but wild-type JAK1-2 signaling pathways. Inhibition of the JAK-STAT signaling pathway by Ruxolitinib results in a dramatic decrease in levels of inflammatory cytokines, such as IL-6 and TNF-α. It is with this attenuation of the inflammatory response that the clinical efficiency of Ruxolitinib is attributed .
Ruxolitinib is approved for the treatment of the MPNs, myelofibrosis, and polycythemia vera.Pre-clinical data suggest that Ruxolitinib shows potential in the treatment of inflammatory conditions such as acute graft versus host disease (GvHD) .
Application of Ruxolitinib
1.Myelofibrosis (a bone marrow disease) that is intermediate or high-risk.
2. Primary myelofibrosis.
3.Post-polycythemia vera myelofibrosis.
4.Post-essential thrombocythemia myelofibrosis.
){kind=link}